Global Cancer Vaccines Market Analysis to 2026 - Featuring Aduro BioTech, Astellas Pharma & AstraZeneca Among Others -

·4-min read

The "Global Cancer Vaccines Market Analysis 2019" report has been added to's offering.

The Global Cancer Vaccines market is growing at a CAGR of 18.7% from 2018 to 2026.

Cancer vaccines are a kind of biological treatment that avoids and heals different sorts of cancer diseases, for example, cervical cancer, prostate cancer, lung cancer, breast cancer, and others. They are designed specifically to recognize and decrease the growth of cancer cells by the immune system. Besides, cancer vaccines are expected to decrease the prevalence and incidence rate of cancer. Factors for example, increasing occurrence of human papilloma virus (HPV) infections and high government investments for the advancement of these vaccines are driving the market growth. Though, longer time span required for manufacturing a single product and high cost for developing these vaccines are projected to inhibit the growth of the market.

By treatment method, preventive vaccine segment acquired significant growth in the market as they are the intended to prevent cancer in healthy people. These vaccines work by preventing infectious agents that cause or contribute to the development of cancer. Most of the preventive vaccines stimulate the production of antibodies, which bind to specific targeted microbes and block their ability to cause infection.

The key vendors mentioned are Aduro BioTech Inc, Astellas Pharma Inc, AstraZeneca PLC, Bavarian Nordic, Bharat Biotech, Bristol-Myers Squibb, Dendreon, Dynavax Technologies Corporation, Emergent Biosolutions, Galena Biopharma, Gamma Vaccines Pty Limited, GlaxoSmithKline, Gritstone Oncology, ImmunoBiology Ltd, Immunomic Therapeutics Inc, Merck & Co Inc, Novavax Inc, OSE Immunotherapeutics, PaxVax Corporation, Prokarium, Sanofi, Sinovac Biotech Ltd and VBI Vaccines Inc.

Key Questions Answered in this Report:

  • How this market evolved since the year 2016

  • Market size estimations, forecasts and CAGR for all the segments presented in the scope

  • Key Market Developments and financials of the key players

  • Opportunity Analysis for the new entrants

  • SWOT Analysis of the key players

  • Fastest growing markets analysed during the forecast period

Key Topics Covered:

1 Market Synopsis

2 Research Outline

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Cancer Vaccines Market, By Treatment Method

5.1 Introduction

5.2 Therapeutic Vaccine

5.3 Preventive Vaccine

6 Global Cancer Vaccines Market, By Technology

6.1 Introduction

6.2 Antigen/Adjuvant Cancer Vaccines

6.3 Dendritic Cells (DC) Cancer Vaccines

6.4 Recombinant Cancer Vaccines

6.5 Viral Vector and DNA Cancer Vaccines

6.6 Whole Cell Cancer Vaccines

7 Global Cancer Vaccines Market, By Type

7.1 Introduction

7.2 Conjugate Vaccines

7.3 Inactivated Vaccines

7.4 Live Attenuated Vaccines

7.5 Recombinant Vector Vaccines

7.6 Subunit Vaccines

7.7 Viral Vector and DNA Vaccines

8 Global Cancer Vaccines Market, By Application

8.1 Introduction

8.2 Breast cancer

8.3 Cervical Cancer

8.4 Lung cancer

8.5 Prostate Cancer

9 Global Cancer Vaccines Market, By End User

9.1 Introduction

9.2 Adults

9.3 Pediatrics

10 Global Cancer Vaccines Market, By Geography

10.1 North America

10.2 Europe

10.3 Asia Pacific

10.4 South America

10.5 Middle East & Africa

11 Strategic Benchmarking

12 Vendors Landscape

12.1 Aduro BioTech Inc

12.2 Astellas Pharma Inc

12.3 AstraZeneca PLC

12.4 Bavarian Nordic

12.5 Bharat Biotech

12.6 Bristol-Myers Squibb

12.7 Dendreon

12.8 Dynavax Technologies Corporation

12.9 Emergent Biosolutions

12.10 Galena Biopharma

12.11 Gamma Vaccines Pty Limited

12.12 GlaxoSmithKline

12.13 Gritstone Oncology

12.14 ImmunoBiology Ltd

12.15 Immunomic Therapeutics Inc

12.16 Merck & Co Inc

12.17 Novavax Inc

12.18 OSE Immunotherapeutics

12.19 PaxVax Corporation

12.20 Prokarium

12.21 Sanofi

12.22 Sinovac Biotech Ltd

12.23 VBI Vaccines Inc

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900